WO2001087255A1 - External application for enhancing the skin permeability of the active components therein - Google Patents

External application for enhancing the skin permeability of the active components therein Download PDF

Info

Publication number
WO2001087255A1
WO2001087255A1 PCT/KR2001/000788 KR0100788W WO0187255A1 WO 2001087255 A1 WO2001087255 A1 WO 2001087255A1 KR 0100788 W KR0100788 W KR 0100788W WO 0187255 A1 WO0187255 A1 WO 0187255A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
composition
absoφtion
external application
linkage
Prior art date
Application number
PCT/KR2001/000788
Other languages
French (fr)
Inventor
Eui Seok Shin
Jang Young Lee
Mu Sung Kim
Sung Gu Lee
Dong Chul Lee
Byung Young Kang
Original Assignee
Pacific Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacific Corporation filed Critical Pacific Corporation
Priority to EP01932343A priority Critical patent/EP1282393B1/en
Priority to DE60114801T priority patent/DE60114801T2/en
Priority to AU2001258876A priority patent/AU2001258876A1/en
Priority to JP2001583724A priority patent/JP5013648B2/en
Priority to AT01932343T priority patent/ATE308967T1/en
Priority to US10/276,176 priority patent/US20040022753A1/en
Publication of WO2001087255A1 publication Critical patent/WO2001087255A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/602Glycosides, e.g. rutin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70Biological properties of the composition as a whole

Definitions

  • the present invention relates to an external application for enhancing the skin absorbency of the active agent infused therein, more specifically, relates to an external application having enhanced skin absorbency of the active agents by using protease stabilized by ⁇ -l,3-glucan branched with ⁇ -l,6-linkage as an agent for enhancing the skin abso ⁇ tion.
  • Skin is divided into three portions, a stratum corneum, epidermal layer and dermis, and the most important barrier for skin absorption of the active agent contained in the external application such as cosmetics is the stratum corneum located on the outermost portion.
  • the stratum corneum is composed of corneous cell mainly comprising keratins and lipid layer filling the space between corneous cells, liposoluble active agents are well absorbed into the skin while water- soluble agents and large-molecule agents are not. Therefore, most of the agents infused in the external applications such as cosmetics are not easily absorbed into the skin, because they are water-soluble.
  • some patents teach other methods for enhancing the skin abso ⁇ tion of the active agents by modifying or weakening the skin barrier function with enzyme.
  • U.S. Patent Nos. 5,534,260 and 5,296,222 show methods for enhancing the abso ⁇ tion of the active agents by adding protease.
  • the above methods are just adding protease into the composition, and therefore, the protease is degenerated or loses its activity with time by the effects of other elements infused in the formulation.
  • the enzyme active agent
  • the above methods are not suitable for external application comprising a lot of elements in addition to the active agent.
  • inventors of the present invention searched for a method for enhancing the skin abso ⁇ tion of the active agents infused in the external application such as cosmetics, and finally found that when protease stabilized by ⁇ -l,3-glucan branched with ⁇ -l,6-linkage is used as an agent for enhancing the skin abso ⁇ tion in the external application, the abso ⁇ tion rate is increased.
  • an object of the present invention is to provide a composition for external application to the skin having the properties of enhanced skin absorbency of the active agents infused in the composition.
  • the present invention provides a composition for external skin application with enhanced skin abso ⁇ tion properties by using protease stabilized by ⁇ -l,3-glucan branched with ⁇ -l,6-linkage as skin abso ⁇ tion enhancing agent in the skin external application.
  • Said composition enhances the skin abso ⁇ tion by modifying the structure of the corneous layer or removing the layer without causing skin stimulus.
  • a method for preparing the protease used as a skin abso ⁇ tion enhancing agent of the present composition complies with the method described in KR 2000-60771 Al (published on Oct. 16, 2000) entitled "Method for preparing stabilized enzyme or protein, and composition for external application comprising the stabilized enzyme or protein provided by the method".
  • the method for stabilizing the protease comprises the steps of; (1) reacting a glucan with periodates to transform the ⁇ -l,6-linkage of the glucan into aldehyde; (2) removing unreacted periodates from the reaction solution of step (1); (3) adding a protease to the reaction solution of step (2) in an amount of 0.00001 ⁇ 10.0% by weight; (4) adding a reducing agent to the reaction solution of step (3) in an amount of 0.0001 ⁇ 1.0% by weight; and (5) washing the product of step (4).
  • Glucans used in the above method are ⁇ -l,3-glucans branched with ⁇ - 1,6-linkage, and the glucans can make functional groups only in the ⁇ -1,6- linkage depending on the chemical reaction.
  • Glucans used in the present invention are not restricted, preferably schizophyllan derived from Schizopyllum commune, scleroglucan derived from Sclerotinia sp. and lentinan derived from Lentinus edodes are used.
  • proteases stabilized by the method of the present invention are not restricted, preferably papain, chymotrypsin, trypsin, carboxypepidase, pepsin, et al. are used.
  • the amount of the stabilized protease contained in the composition of the external application is 0.0001 ⁇ 99.9999 % by weight on the basis of the weight of total composition.
  • formulation for external application is not restricted.
  • they may have cosmetic formulation such as skin softener, nutrition water, massage cream, make-up base, lipstick, pack, gel, shampoo, rinse, hair tonic or soap, or external dermatological formulation such as lotion, ointment, gel, cream, patch or spray.
  • the sorts of active agents having their skin abso ⁇ tion properties enhanced by the skin abso ⁇ tion enhancers of the present invention are conventional active agents, and are not restricted specifically.
  • water-soluble derivatives of L-ascorbic acid such as L-ascorbic acid, L-ascorbic phosphate, L-ascorbic glucoside, et al., vitamin B, kojic acid, kojic caffeine acid, kojic aminopropyl phosphate, hydroquinone, albutine, water soluble natural extract derived from green tea or grape by water or ethanol, et al. are used as active agents.
  • step 4) Ingredient 8 was added to the solution of step 3) to form a gel. 5) Gas bubbles were removed by vacuum deaeration, then a water-gel type cosmestic was obtained.
  • the amount of the ascorbic acid absorbed into the skin was measured with the method described in Experimental Example 1 except that water-in-oil type cosmetic composition of Example 2 and Comparative Example 3 were used. The results are shown in Table 2.
  • Table 2 shows that when a stabilized protease is added to the composition, the skin abso ⁇ tion of ascorbic acid is increased by about six times compared with a case that a stabilized protease is not added.
  • A(ingredients 1-9 and ingredient 17) and B (ingredients 10-12) were heated to 75 °C.
  • the amount of the hydroquinone absorbed into the skin was measured with the method described in Experimental Example 1 except that ointments prepared in the Example 3 and Comparative Example 5 were used. The results are shown in Table 3.
  • Table 3 shows that when a stabilized protease is added to the composition, the skin abso ⁇ tion of hydroquinone is increased by about six times compared with a case that a stabilized protease is not added.
  • the amount of the kojic acid absorbed into the skin was measured with the method described in Experimental Example 1 except that aqueous gel type cosmetic compositions of Example 1 and Comparative Example 2 after 30 days of their preparation were used. The results are shown in Table 4.
  • Table 4 shows that although papain is contained in the cosmetic composition, as shown in case of comparative example 2 that do not comprise stabilized papain, papain loses its activity after 30 days of its preparation by the effects of the other ingredients contained together, therefore papain no longer shows the skin abso ⁇ tion enhancement.
  • Experimental Example 5 Measurement for skin abso ⁇ tion of the ascorbic acid infused in the water-in-oil cosmetic composition after 30 days of its preparation The amount of the ascorbic acid absorbed into the skin was measured with the method described in Experimental Example 2 except that water-in-oil type cosmetic compositions of Example 2 and Comparative Example 4 after 30 days of their preparation were used. The results are shown in Table 5.
  • Table 5 shows that although papain is contained in the cosmetic composition, as shown in the case of comparative example 4 that does not comprise stabilized papain, papain loses its activity after 30 days of its preparation by the effects of the other ingredients contained together, therefore papain no longer shows the skin abso ⁇ tion enhancement.
  • Table 6 shows that although papain is contained in the cosmetic composition, as shown in case of comparative example 6 that does not comprise stabilized papain, papain loses its activity after 30 days of its preparation by the effects of the other ingredients contained together, therefore papain no longer shows the skin abso ⁇ tion enhancement.
  • the skin abso ⁇ tion enhancers of the present invention do not cause skin problems such as skin stimuli, skin injury, et al., but the do enhance the skin abso ⁇ tion of the components that have problems in permeation because of they have low affinity to the corneous layer or high molecular weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a composition for external application enhancing the skin absorption of the active components infused in the composition, more specifically relates to an external application having enhanced skin permeability of the active components by using protease stabilized by β-1,3-glucan branched with β-1,6-linkage as an agent for enhancing the skin permeability to weaken the wall properties of the corneous layer.

Description

External application for enhancing the skin permeability of the active components therein
FIELD OF THE INVENTION
The present invention relates to an external application for enhancing the skin absorbency of the active agent infused therein, more specifically, relates to an external application having enhanced skin absorbency of the active agents by using protease stabilized by β-l,3-glucan branched with β-l,6-linkage as an agent for enhancing the skin absoφtion.
BACKGROUND OF THE INVENTION
Skin is divided into three portions, a stratum corneum, epidermal layer and dermis, and the most important barrier for skin absorption of the active agent contained in the external application such as cosmetics is the stratum corneum located on the outermost portion.
Especially, because the stratum corneum is composed of corneous cell mainly comprising keratins and lipid layer filling the space between corneous cells, liposoluble active agents are well absorbed into the skin while water- soluble agents and large-molecule agents are not. Therefore, most of the agents infused in the external applications such as cosmetics are not easily absorbed into the skin, because they are water-soluble.
Conventionally, to solve these problems, using non-polar solvents, surfactants, and lipid acid, et al. as skin absoφtion enhancers is disclosed. [Chen LH, Chien YW, "Enhancement of skin penetration" In "Novel cosmetic delivery systems" 1990, 60; Rhein LD, Robbins CR, Fernee K, Cantore R. "Surfactant structure effects on swelling of isolated human stratum corneum", J. Soc. Cosmet Chem. 1986, 37: 125; Cooper ER, Merritt EW, Smith RL., "Effect of fatty acids and alcohols on the penetration of acylclovir across human skin in vitro," J. Pharm. Sci. 1985; 74: 688]. However, although these skin absoφtion enhancers enhance the skin-absoφtion of the active agent, they cause fierce skin stimuli after being absorbed into the skin because their molecular weights are small. Further, applying sonophoresis or minute iontophoresis on the skin to enhance the skin absoφtion of the water-soluble materials to the skin is also disclosed. [Sloan JB, Slotani K. "Iontophoresis in dermatology: a review" J. Am. Acad. Dermatol. 1986, 4:671; Langer R. "Ultrasound-mediated transdermal protein delivery" Science 1995; 269:850] However, because these methods need expensive equipments, these methods are not practically used in the external applications such as cosmetic compositions.
In addition, some patents teach other methods for enhancing the skin absoφtion of the active agents by modifying or weakening the skin barrier function with enzyme. For example, U.S. Patent Nos. 5,534,260 and 5,296,222 show methods for enhancing the absoφtion of the active agents by adding protease. However, the above methods are just adding protease into the composition, and therefore, the protease is degenerated or loses its activity with time by the effects of other elements infused in the formulation. As can be estimated above, because the enzyme (active agent) does not accomplish enhanced skin absoφtion, the above methods are not suitable for external application comprising a lot of elements in addition to the active agent.
To solve above-mentioned problems, inventors of the present invention searched for a method for enhancing the skin absoφtion of the active agents infused in the external application such as cosmetics, and finally found that when protease stabilized by β-l,3-glucan branched with β-l,6-linkage is used as an agent for enhancing the skin absoφtion in the external application, the absoφtion rate is increased. SUMMARY OF THE INVENTION
Therefore, an object of the present invention is to provide a composition for external application to the skin having the properties of enhanced skin absorbency of the active agents infused in the composition.
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention is described in detail.
The present invention provides a composition for external skin application with enhanced skin absoφtion properties by using protease stabilized by β-l,3-glucan branched with β-l,6-linkage as skin absoφtion enhancing agent in the skin external application. Said composition enhances the skin absoφtion by modifying the structure of the corneous layer or removing the layer without causing skin stimulus. A method for preparing the protease used as a skin absoφtion enhancing agent of the present composition complies with the method described in KR 2000-60771 Al (published on Oct. 16, 2000) entitled "Method for preparing stabilized enzyme or protein, and composition for external application comprising the stabilized enzyme or protein provided by the method". In detail, the method for stabilizing the protease comprises the steps of; (1) reacting a glucan with periodates to transform the β-l,6-linkage of the glucan into aldehyde; (2) removing unreacted periodates from the reaction solution of step (1); (3) adding a protease to the reaction solution of step (2) in an amount of 0.00001 ~ 10.0% by weight; (4) adding a reducing agent to the reaction solution of step (3) in an amount of 0.0001 ~ 1.0% by weight; and (5) washing the product of step (4).
Glucans used in the above method are β-l,3-glucans branched with β- 1,6-linkage, and the glucans can make functional groups only in the β-1,6- linkage depending on the chemical reaction. Glucans used in the present invention are not restricted, preferably schizophyllan derived from Schizopyllum commune, scleroglucan derived from Sclerotinia sp. and lentinan derived from Lentinus edodes are used.
In addition, proteases stabilized by the method of the present invention are not restricted, preferably papain, chymotrypsin, trypsin, carboxypepidase, pepsin, et al. are used.
The amount of the stabilized protease contained in the composition of the external application is 0.0001 ~ 99.9999 % by weight on the basis of the weight of total composition. Further, formulation for external application is not restricted. For example, they may have cosmetic formulation such as skin softener, nutrition water, massage cream, make-up base, lipstick, pack, gel, shampoo, rinse, hair tonic or soap, or external dermatological formulation such as lotion, ointment, gel, cream, patch or spray.
In addition, the sorts of active agents having their skin absoφtion properties enhanced by the skin absoφtion enhancers of the present invention are conventional active agents, and are not restricted specifically. For example, water-soluble derivatives of L-ascorbic acid such as L-ascorbic acid, L-ascorbic phosphate, L-ascorbic glucoside, et al., vitamin B, kojic acid, kojic caffeine acid, kojic aminopropyl phosphate, hydroquinone, albutine, water soluble natural extract derived from green tea or grape by water or ethanol, et al. are used as active agents.
Hereinafter, the present invention is described more specifically with the embodiments of the present invention, however, the scope of the present invention is not restricted within the embodiments. DESCRIPTION OF THE PREFERRED EMBODIMENTS
<Reference Example 1> Preparation of stabilized Papain
1) To 50 ml of 0.5wt% aqueous solution of sschizophyllan (molecular weight of 2,000,000), 2g of sodium iodide peroxide (NaI04) was added, and the resulting mixture was kept in the dark at 4 °C for 1 hour with stirring.
2) The resulting schizophyllan solution was subjected to dialysis over membrane (MW cut off 10,000) in the dark for 48 hours. The dialysis was carried out with replacements of 2500ml water every 12 hours.
3) When the volume of the schizophyllan solution was increased to about 100ml, 0.1 wt% of papain was added, and the resulting solution was stirred for 2 hours in the dark at 4°C.
4) 0.05g of sodium borohydride (NaBH4) was added to the schizophyllan -papain solution, and followed by stirring for 4 hours. Then, O.lg of lysine was added and the resulting mixture was stirred for 2 hours in the dark at 4°C.
5) The resulting schizophyllan-papain solution was subjected to the dialysis as described in the step 2) to obtain a solution of papain coupled to schizophyllan (GE-1). The yield of the GE-1 prepared was
95% based on the enzyme activity.
<Example 1 and Comparative Example 1 and 2> Water-gel type cosmestics
Figure imgf000007_0001
<Method for preparation>
1) Ingredients 1~7 were added to the distilled water, then completely dissolved by stirring.
2) Ingredients 10 ~ 12 were added to the ethanol, then completely dissolved by stirring.
3) Solution prepared in step 2) was slowly added to the solution prepared in step 1) while stirring the solution.
4) Ingredient 8 was added to the solution of step 3) to form a gel. 5) Gas bubbles were removed by vacuum deaeration, then a water-gel type cosmestic was obtained.
<Example 2 and Comparative Example 3 and 4> Water-in-Oil type emulsion cosmestics
Figure imgf000008_0001
<Method for preparation> 1) Component A (ingredient 1-7) and Component B (ingredient 8-10) were heated to 75 °C.
2) A was slowly added to B while stirring at 7,000 rpm. After completely adding A to B, ingredients 14 and 16 were added to the mixture immediately, then stirred for two minute to emulsify.
3) Ingredients 11 and 15 were added and stirred for two minute to emulsify.
4) Mixture of 3) was stirred for 1 minute at 2,500 φm to remove air.
5) Mixture of 4) was cooled in an ice bath to 28~30°C.
6) Ingredient 12 or 13 was added to the above cooled mixture, then stirred with 2,000 φm.
7) The product was left to stand at room temperature for 24 hours to obtain a stabilized water-in-oil type cosmetic composition.
Experimental Example 1> Measurement for skin absoφtion of the kojic acid
Measurement for skin absoφtion of the kojic acid was practiced in the Frantz permeation cells using the skins of a guinea pig. Abdominal skin was obtained from the guinea pig before the experiment. Above obtained skin was cut to a dimension of 1cm , and stood in the permeation cell having the diameter of the permeation lens 0.9cm, then held by the clamp. 0.5 ml of cosmetic compositions from Example 1 and Comparative Example 1 to be tested were applied on one side of the skin, while the other side of the skin was contacted with solvent mixture of distilled water and glycerin with the ratio of 1 : 1. The temperature was maintained at 32°C, which is the skin temperature. The solvent was collected periodically (with fixed time interval; hour), then the amount of the kojic acid absorbed into the skin was measured by HPLC. The results are shown in Table 1. <Table 1> Skin absoφtion of the kojic acid per applying density(μm/cm2/wt%)
Figure imgf000010_0001
Considering that the duration time of general make-up is 4-8 hours, table
1 shows that when a stabilized protease is added to the composition, the skin absoφtion of kojic acid is increased by about four times compared with a case that a stabilized protease is not added.
Experimental Example 2> Measurement for skin absoφtion of the ascorbic acid
The amount of the ascorbic acid absorbed into the skin was measured with the method described in Experimental Example 1 except that water-in-oil type cosmetic composition of Example 2 and Comparative Example 3 were used. The results are shown in Table 2.
<Table 2> Skin absoφtion of the ascorbic acid (μm/cm2/wt%)
Figure imgf000010_0002
Table 2 shows that when a stabilized protease is added to the composition, the skin absoφtion of ascorbic acid is increased by about six times compared with a case that a stabilized protease is not added.
<Example 3 and Comparative Example 5 and 6> Ointment
Figure imgf000011_0001
<Method for preparation>
1) A(ingredients 1-9 and ingredient 17) and B (ingredients 10-12) were heated to 75 °C.
2) A was slowly added to B, and the mixture was stirred at 7,500 φm for 5 minutes to emulsify.
3) Ingredient 13 was added to the mixture, and stirred at 7,500 φm for 5 minutes to emulsify.
4) Mixture of 3) was cooled in an ice bath to 25°C.
5) Ingredients 14 - 16 were added, and stirred at 2,500 φm for mixing.
6) The product was left to stand at room temperature for 24 hours to obtain ointment.
Experimental Example 3> Measurement for skin absoφtion of hydroquinone
The amount of the hydroquinone absorbed into the skin was measured with the method described in Experimental Example 1 except that ointments prepared in the Example 3 and Comparative Example 5 were used. The results are shown in Table 3.
<Table 3> Skin absoφtion of the hydroquinone (μm/cm2/wt%)
Figure imgf000012_0001
Table 3 shows that when a stabilized protease is added to the composition, the skin absoφtion of hydroquinone is increased by about six times compared with a case that a stabilized protease is not added.
Experimental Example 4> Measurement for skin absoφtion of the kojic acid infused in the aqueous gel type cosmetic composition after 30 days of its preparation
The amount of the kojic acid absorbed into the skin was measured with the method described in Experimental Example 1 except that aqueous gel type cosmetic compositions of Example 1 and Comparative Example 2 after 30 days of their preparation were used. The results are shown in Table 4.
<Table 4> Skin absoφtion of the kojic acid (μm/cm /wt%)
Figure imgf000013_0001
Table 4 shows that although papain is contained in the cosmetic composition, as shown in case of comparative example 2 that do not comprise stabilized papain, papain loses its activity after 30 days of its preparation by the effects of the other ingredients contained together, therefore papain no longer shows the skin absoφtion enhancement.
Experimental Example 5> Measurement for skin absoφtion of the ascorbic acid infused in the water-in-oil cosmetic composition after 30 days of its preparation The amount of the ascorbic acid absorbed into the skin was measured with the method described in Experimental Example 2 except that water-in-oil type cosmetic compositions of Example 2 and Comparative Example 4 after 30 days of their preparation were used. The results are shown in Table 5.
<Table 5> Skin absoφtion of the ascorbic acid (μm/cm2/wt%)
Figure imgf000014_0001
Table 5 shows that although papain is contained in the cosmetic composition, as shown in the case of comparative example 4 that does not comprise stabilized papain, papain loses its activity after 30 days of its preparation by the effects of the other ingredients contained together, therefore papain no longer shows the skin absoφtion enhancement.
Experimental Example 6> Measurement for skin absoφtion of hydroquinone confused in the ointment after 30 days of its preparation
The amount of the hydroquinone absorbed into the skin was measured with the method described in Experimental Example 3 except that ointments of Example 3 and Comparative Example 6 after 30 days of their preparation were used. The results are shown in Table 6. <Table 6> Skin absoφtion of the hydroquinone (μm/cm2/wt%)
Figure imgf000015_0001
Table 6 shows that although papain is contained in the cosmetic composition, as shown in case of comparative example 6 that does not comprise stabilized papain, papain loses its activity after 30 days of its preparation by the effects of the other ingredients contained together, therefore papain no longer shows the skin absoφtion enhancement.
Experimental Example 7> Observation of the skin injury
The external applications prepared in Examples 1 to 3 were applied on the skin of the guinea pig as described in the Experimental Example 1. When 24 hours had passed after applying, the skin was taken out from the Frantz permeation cell to be observed with naked eyes.
As the result of the observation, skin injury was not observed in the case of Examples 1 to 3, and it was found that stabilized protease do not cause skin injury but enhances skin absoφtion of the active agents.
Experimental Example 8> Skin stabilization
To examine the skin stabilization function of the protease, 300 ml of the external applications prepared in Examples 1 to 3 were applied on the same position of the back of nude mouse once a day for 30 days to observe the skin injuries such as swelling, erythema, et al. with naked eyes. However, no skin injury was observed.
The skin absoφtion enhancers of the present invention do not cause skin problems such as skin stimuli, skin injury, et al., but the do enhance the skin absoφtion of the components that have problems in permeation because of they have low affinity to the corneous layer or high molecular weight.

Claims

1. A composition for external application comprising at least one active agent, wherein the skin absoφtion of said active agent is enhanced by comprising a protease that is stabilized by a skin absoφtion enhancing agent β- 1 ,3 -glucan branched with β- 1 ,6-linkage.
2. A composition of claim 1, wherein said active agent is selected from the group consisting of L-ascorbic acid, derivatives of L-ascorbic acid, vitamin B, kojic acid, kojic caffeine acid, kojic aminopropyl phosphate, hydroquinone, albutine and water soluble natural.
3. A composition of claim 1, wherein said β- 1,3 -glucan branched with β-
1,6-linkage is schizophyllan, scleroglucan or lentinan.
4. A composition of claim 1, wherein said proteases is selected from the group consisting of papain, trypsin, chymotrypsin, carboxypepidase and pepsin.
5. A composition of claim 1, wherein said proteases is stabilized by the method comprising the steps of;
(1) reacting β- 1,3 -glucan branched with β-l,6-linkage and periodates to transform the β-l,6-linkage of the glucan into aldehyde;
(2) removing unreacted periodates from the reaction solution of step (1);
(3) adding a protease to the reaction solution of step (2) in an amount of 0.00001 - 10.0% by weight;
(4) adding a reducing agent to the reaction solution of step (3) in an amount of 0.0001 ~ 1.0% by weight; and (5) washing the product of step (4).
PCT/KR2001/000788 2000-05-16 2001-05-16 External application for enhancing the skin permeability of the active components therein WO2001087255A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP01932343A EP1282393B1 (en) 2000-05-16 2001-05-16 External application for enhancing the skin permeability of the active components therein
DE60114801T DE60114801T2 (en) 2000-05-16 2001-05-16 PREPARATION FOR EXTERNAL USE TO IMPROVE THE PERMEABILITY OF THE SKIN FOR ACTIVE SUBSTANCES
AU2001258876A AU2001258876A1 (en) 2000-05-16 2001-05-16 External application for enhancing the skin permeability of the active components therein
JP2001583724A JP5013648B2 (en) 2000-05-16 2001-05-16 Composition for enhancing skin absorption of active ingredient in external preparation for skin
AT01932343T ATE308967T1 (en) 2000-05-16 2001-05-16 PREPARATION FOR EXTERNAL USE TO IMPROVE THE PERMEABILITY OF THE SKIN TO ACTIVE INGREDIENTS
US10/276,176 US20040022753A1 (en) 2000-05-16 2001-05-16 External application for enhancing the skin permeability of the active components therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020000026086A KR100338327B1 (en) 2000-05-16 2000-05-16 External application for enhancing the skin permeability of the active components therein
KR2000/26086 2000-05-16

Publications (1)

Publication Number Publication Date
WO2001087255A1 true WO2001087255A1 (en) 2001-11-22

Family

ID=19668725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2001/000788 WO2001087255A1 (en) 2000-05-16 2001-05-16 External application for enhancing the skin permeability of the active components therein

Country Status (9)

Country Link
US (1) US20040022753A1 (en)
EP (1) EP1282393B1 (en)
JP (1) JP5013648B2 (en)
KR (1) KR100338327B1 (en)
CN (1) CN1457253A (en)
AT (1) ATE308967T1 (en)
AU (1) AU2001258876A1 (en)
DE (1) DE60114801T2 (en)
WO (1) WO2001087255A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100338327B1 (en) * 2000-05-16 2002-08-07 주식회사 태평양 External application for enhancing the skin permeability of the active components therein
WO2003047629A2 (en) * 2001-11-29 2003-06-12 Molecular Skincare Limited Treatment of diseases via the skin
WO2006015627A1 (en) * 2004-08-13 2006-02-16 Symrise Gmbh & Co. Kg β-(1,3)-β-(1,4)-GLUCAN AS CARRIER FOR CHEMICAL SUBSTANCES
EP1720605A2 (en) * 2003-06-23 2006-11-15 Transpharma Medical Ltd. Transdermal delivery system for cosmetic agents
WO2010105842A2 (en) 2009-03-19 2010-09-23 Bubbles And Beyond Gmbh Preparation for external application
WO2011061144A2 (en) 2009-11-20 2011-05-26 Basf Se The present invention relates to the use of beta-(1, 3)- beta-(1, 4) glucan with an average molecular weight of from 5.000 to 150.000 da for the increase of synthesis of collagen

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100447055B1 (en) * 2001-07-30 2004-09-04 주식회사 참 존 Technical procedure of modified Alternan production and enzyme stabilization
KR20030082765A (en) * 2002-04-18 2003-10-23 한국화학연구원 Transdermal drug delivery matrix type system contained hydroquinone and cosmetic ingredients
KR100507960B1 (en) * 2002-10-22 2005-08-19 (주)나노팜 Composition of removing corneum, method of preparing the same and cleansing composition including the same
JP4626202B2 (en) * 2003-07-16 2011-02-02 大正製薬株式会社 Piroxicam-containing external anti-inflammatory analgesic composition
DE102004010940B4 (en) 2004-03-05 2012-01-26 Erbe Elektromedizin Gmbh Neutral electrode for HF surgery
EP1609460A1 (en) * 2004-06-24 2005-12-28 The Procter & Gamble Company Skin care compositions comprising fatty material having a melting temperature range of 21-40 C
EP1824499A2 (en) * 2004-12-10 2007-08-29 Alcon Inc. Compositions for treatment of ear infections
WO2007119467A1 (en) * 2006-03-23 2007-10-25 Cosmed Pharmaceutical Co., Ltd. Percutaneous absorption promoting agent and percutaneous absorption preparation using the same
US20080160043A1 (en) * 2007-07-16 2008-07-03 Kim Moo-Sung Preparation method of beta-glucan from schizophyllum commune and composition for external application comprising the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03209333A (en) * 1990-01-10 1991-09-12 Nippon Chem Res Kk Agent for suppressing proliferation of herpes virus and inhibiting relapse after latent infection
WO1999015210A2 (en) * 1997-09-26 1999-04-01 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
KR20000060771A (en) * 1999-03-19 2000-10-16 서경배 A method for stabilizing enzymes or proteins and compositions for external application containing enzymes or proteins stabilized thereby

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61282313A (en) * 1985-06-06 1986-12-12 Nitto Electric Ind Co Ltd Enzyme-containing plaster
US5156846A (en) * 1989-02-23 1992-10-20 University Of Utah Percutaneous drug delivery system
JP3000488B2 (en) * 1991-03-07 2000-01-17 株式会社コーセー Cosmetics
JPH06321733A (en) * 1993-05-07 1994-11-22 Noevir Co Ltd Sheetlike pack agent and its production
US5441740A (en) * 1994-05-06 1995-08-15 Longevity Network. Ltd. Cosmetic composition containing alpha hydroxyacids, salicyclic acid, and enzyme mixture of bromelain and papain
JPH09176029A (en) * 1995-12-26 1997-07-08 Shigenobu Sakata Outer cortex function-stimulating and infection-preventing liquid and its production
CN1244317C (en) * 1996-08-02 2006-03-08 株式会社资生堂 Composition for enhancing hyaluronic acid productivity and method for preparing same
US6162419A (en) * 1996-11-26 2000-12-19 Nicholas V. Perricone Stabilized ascorbyl compositions
FR2761363B1 (en) * 1997-03-28 1999-11-26 Oreal PURIFYING SKIN POLYPEPTIDE AND ITS USE
FR2781668B1 (en) * 1998-07-31 2001-06-01 Oreal SKIN TREATMENT PROCESS AND PATCH FOR IMPLEMENTING THE PROCESS
KR100338327B1 (en) * 2000-05-16 2002-08-07 주식회사 태평양 External application for enhancing the skin permeability of the active components therein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03209333A (en) * 1990-01-10 1991-09-12 Nippon Chem Res Kk Agent for suppressing proliferation of herpes virus and inhibiting relapse after latent infection
WO1999015210A2 (en) * 1997-09-26 1999-04-01 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
KR20000060771A (en) * 1999-03-19 2000-10-16 서경배 A method for stabilizing enzymes or proteins and compositions for external application containing enzymes or proteins stabilized thereby

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100338327B1 (en) * 2000-05-16 2002-08-07 주식회사 태평양 External application for enhancing the skin permeability of the active components therein
WO2003047629A2 (en) * 2001-11-29 2003-06-12 Molecular Skincare Limited Treatment of diseases via the skin
WO2003047629A3 (en) * 2001-11-29 2003-08-28 Molecular Skincare Ltd Treatment of diseases via the skin
EP1720605A2 (en) * 2003-06-23 2006-11-15 Transpharma Medical Ltd. Transdermal delivery system for cosmetic agents
JP2007521258A (en) * 2003-06-23 2007-08-02 トランスファーマ メディカル リミテッド Transdermal delivery system for cosmetics
EP1720605A4 (en) * 2003-06-23 2007-10-24 Transpharma Medical Ltd Transdermal delivery system for cosmetic agents
WO2006015627A1 (en) * 2004-08-13 2006-02-16 Symrise Gmbh & Co. Kg β-(1,3)-β-(1,4)-GLUCAN AS CARRIER FOR CHEMICAL SUBSTANCES
WO2010105842A2 (en) 2009-03-19 2010-09-23 Bubbles And Beyond Gmbh Preparation for external application
DE102009013469A1 (en) 2009-03-19 2010-12-09 Bubbles And Beyond Gmbh Preparation for external use
WO2011061144A2 (en) 2009-11-20 2011-05-26 Basf Se The present invention relates to the use of beta-(1, 3)- beta-(1, 4) glucan with an average molecular weight of from 5.000 to 150.000 da for the increase of synthesis of collagen

Also Published As

Publication number Publication date
DE60114801D1 (en) 2005-12-15
DE60114801T2 (en) 2006-11-23
EP1282393B1 (en) 2005-11-09
JP2004507458A (en) 2004-03-11
ATE308967T1 (en) 2005-11-15
KR20010104881A (en) 2001-11-28
CN1457253A (en) 2003-11-19
KR100338327B1 (en) 2002-08-07
EP1282393A1 (en) 2003-02-12
JP5013648B2 (en) 2012-08-29
AU2001258876A1 (en) 2001-11-26
EP1282393A4 (en) 2004-03-31
US20040022753A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
CA2306040C (en) Coloring agent-containing sunless tanning compositions
EP0686386B1 (en) Cosmetic and dermatologic composition comprising a stable aqueous dispersion of phytantriol-based gel particles containing a long-chain surfactant as dispersant and stabilizer
EP1282393B1 (en) External application for enhancing the skin permeability of the active components therein
EP0661035B1 (en) Cosmetic composition for the simultaneous treatment of the superficial skinlayers and the deep skinlayers
EP0754449A1 (en) Skin whitening composition and/or anti-aging composition and uses thereof
US20090130036A1 (en) Self tanning product having slimming, firming and toning properties associated therewith
KR101840045B1 (en) Liposomes encapsulating an oxazolidin-2-one compound
US6645508B1 (en) Stable L-ascorbic acid composition
CN102933192A (en) Topical pharmaceutical or cosmetic composition useful for the treatment of diseases or conditions that transcur through a deficit of maturation of the cornified envelope
CN111743807A (en) Water-oil insoluble transparent ceramide aqueous solution and preparation method thereof
KR20200137431A (en) Composition for skin anti-inflammation and skin moisturizing comprising artemisia extract extracted with skin cosmetic solution as a solvent
KR102233140B1 (en) Cosmetic composition for skin improvement containing low molecular weight hyaluronic acid
EP3777825A1 (en) Composition of freeze-dried formulation, cosmetic kit for external use on skin including the same, and its use
KR101605324B1 (en) Cosmetic composition for moisturizing skin which alleviates itchiness and dryness by removing keratin and increasing moisture
CN115137667A (en) Cosmetic composition with permeation promoting effect and application thereof
CN112891248A (en) Water-oil insoluble ceramide transparent oil solution and preparation method thereof
KR102100820B1 (en) Rosa centifolia flower petal fermented by aureobasidium pullulans
CN112190576A (en) Composition of skin external preparation, skin external preparation and preparation method thereof
KR100306847B1 (en) Cosmetic composition for whole body
KR100737391B1 (en) Nano particle composition comprising the aloe gel and cosmetics containing the same
KR101557422B1 (en) Cleansing composition and cosmetic composition with the extract of Styrax japonica
CN112891270B (en) Cosmetic composition and preparation method and application thereof
KR102656826B1 (en) Cosmetic Composition For Moisturizing Skin Comprising Mixed Extracts of Opuntia Tuna Fruit, Thuja Occidentalis Leaf and Lilium Candidum Bulb
JPS63227512A (en) Cosmetic containing extract of tremella fuciformis
KR20220036434A (en) Cosmetic composition containing fermented water-soluble chitosan having low molecular weight

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001932343

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018091652

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10276176

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001932343

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001932343

Country of ref document: EP